Lund, February 15th 2017
Sweden’s ambassador in the Philippines officially opened ChemoTech’s Centre of Excellence in South East Asia
On February 13-14 2017 Chemotech and Asian Hospital and Medical Centre (AHMC) opened the company’s first Centre of Excellence. Sweden’s ambassador Harald Fries was an honorary guest and opened the centre together with the President and CEO of the AHMC.
“It’s and honour to participate in the launch of a cooperation between a hospital of this dignity and a company which promotes Sweden in such a refined way, as a creative and high-tech country with good moral principles regarding the view of people’s equal value and right to health care”, says the ambassador in his opening speech.
The centre is indented to be the spine of ChemoTech’s ambition to educate and certify doctors in the company’s methods, especially in the Philippines, but it will also be used in ChemoTechs’s further expansions in South East Asia.
About 150 people from the AHMC and other hospitals in Manila were present during the opening. A total of 17 doctors and nurses were trained in treatment with the IQWaveTM on a total of six cancer patients. The training was led by ChemoTech’s application specialist from India and Dr Habito at the AHMC, who visited ChemoTech’s head office in Lund at the end of January and received training in treatment with the IQWaveTM. Dr Habito is now the first doctor in South East Asia who is a certified instructor of the IQWaveTM Dynamic-ElectroEnhanced ChemoTherapyTM
“The cooperation with ChemoTech is the start of a new journey for the AHMC, which means that the new oncology treatment will be available for Filipinos who need it the most.” says Mr Andres Licaros, Jr. President and CEO at AHMC.
Dr Corazon A. Ngelangel, head of the cancer institute at AHMC, says:
“At AHMC we want to thank ChemoTech for offering us their innovative technology and for letting us be their partner in this global fight against cancer.”
ChemoTech are very happy that the letter of intent we signed about a month ago is already put into practice. Now we await the results and evaluations of these six patients, before the AHMC can make a final decision about leasing or buying the IQWaveTM.
The selling of the IQWaveTM in the Philippines is dependent on an acceptance from the Philippine authorities, whose process has begun.
“We are very grateful of the level of dedication we have been given from Sweden’s ambassador in the Philippines and his team at the embassy”, says Mohan Frick, CEO at ChemoTech.
AHMC is owned by the Philippine listed company “Metro Pacific Investments” (MPIC). They own a total of 13 hospitals in the Philippines after their latest acquisition.
For more information, please contact:
Mohan Frick, CEO
+ 46 (0)10-218 93 00
Scandinavian ChemoTech AB (publ)
This information is such information which Scandinavian ChemoTech AB (publ) is obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact persons, to be made public on Wednesday February 15th 2017 at 13.00 (CET).
ChemoTech is a young and dynamic life science corporation which rests on a great medical expertise and technical knowledge. Our latest launch of the IQWaveTM is an innovation in electro chemotherapy, which gently provides an utmost effective treatment of many types of tumors. We have our head office in the IDEON Science Park in Lund and we are in the middle of the stimulating meeting between Skåne University Hospital and Medicon Village. ChemoTech’s stocks (CMOTEC B) are listed at NASDAQ First North in Stockholm and Västra Hamnen Corporate Finance AB is the company’s Certified Adviser.